Background: To evaluate long-term effectiveness of omalizumab in 'real-life' setting of Thai asthmatic patients.
Methods: We conducted multi-center, observational study in severe asthma patients who received omalizumab in Thailand. Outcomes were asthma exacerbation (hospitalization and ER visit), asthma control test (ACT), and daily ICS dose.